Qualitätsbericht 2022 55 | 70 A patterns of care analysis of hyperthermia in combination with radio(chemo)therapy or chemotherapy in European clinical centers. Ademaj A, Veltsista PD, Marder D, Hälg RA, Puric E, Brunner TB, Crezee H, Gabrys D, Franckena M, Gani C, Horsman MR, Krempien R, Lindner LH, Maluta S, Notter M, Petzold G, Abdel-Rahman S, Richetti A, Thomsen AR, Tsoutsou P, Fietkau R, Ott OJ, Ghadjar P, Riesterer O. Strahlenther Onkol. 2022 Aug 29. doi: 10.1007/s00066-022-01980-9. Epub ahead of print. PMID: 36038671. A retrospective study with long term follow-up of Graves’ disease patients treated with low activities of 131 Iodine. Neumann R, Thomman R, Goerres GW. Q J Nucl Med Mol Imaging 2022; 66:000-000. Cancer en cuirasse: Hyperthermie beim rezidivierenden Mammakarzinom. «nothing to do» oder besteht noch eine lokale Therapieoption mit low dose re-Bestrahlung und Oberflächenhyperthermie? Notter, M. Schweizer Zeitschrift für Onkologie 4/2022, 24-29 Effective tumor control following re-irradiation combined with superficial hyperthermia o inoperable, locally recurrent breast cancers. Notter M., Thomsen, A. R., Vaupel, P. J Women’s Health Dev 2022; 5 (1): 050-056 Thermography controlled contact-free wIRA-hyperthermia combined with hypofractionated radiotherapy for large-sized lesions of unresectable, locally recurrent breast cancer. M. Notter, A.R. Thomsen, A.L. Grosu, K. Münch, P. Vaupel In Water-filtered Infrared-A (wIRA) Irradiation, Ed. P. Vaupel, 2022, 83 – 95; htttps://doi.org/10.1007/978-3-030-92880-3_6 Sensitizing Breast Cancer Cells Using Standard Microwave Devices and Temperature Monitoring With Non-Invasive Thermochemical Thermometers Ounalli, L., Notter M. Insights of Biomedical Research Vol. 6, Issue 1, pages 161-174, 2022, Doi: 10.36959/584/463 A novel method of bolus application in hyperthermia of very extended superficial tumors. Notter M. Jour of Clin Cas Rep, Med Imag and Heal Sci 2 (2)-2022, https://doi.org/10.55920/JCRMHS.2022.02.001068 Status der regionalen Hyperthermie in der Schweiz. Stutz, E., Notter, M., Puric, E., Hübenthal, B., Riesterer O. Info@Onco Suisse_08_2022, 10-13 Hyperthermie beim Mammakarzinom Lokalrezidiv. Bucher J., Notter M. Onkologiepflege_02-2022, 10-11 EFOMP policy statement 17: The role and competences of medical physicists and medical physics experts in the different stages of a medical device life cycle. Asten, Wim & Markidou, Erato & Gromoll, Christian & Gourzoulidis, George & Maguire, Susan & Guidi, Gabriele & Pace, Eric & Spruijt, Hugo & Martinez-Ortega, Jaime & Klöck, Stephan. (2022). Physica Medica. 104. S18. 10.1016/S1120-1797 (22) 02155-X. Ophthalmologie Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers. Munk MR, Somfai GM, de Smet MD, Donati G, Menke MN, Garweg JG, Ceklic L. The Int J Mol Sci. 2022 Jul 8;23(14):7585. doi: 10.3390/ijms23147585. PMID: 35886930; PMCID: PMC9319632. Long-term Efficacy of TNF-alpha Inhibitors on Persistent Uveitic Macular Edema: A Swiss Multicenter Cohort Study. Bograd A, Fuchs D, Bächtiger J, Pfister IB, Spindler J, Hoogewoud F, Gugleta K, Böni C, Guex-Crosier Y, Garweg JG, Tappeiner C. Ocul Immunol Inflamm. 2022 May 19:1-8. doi: 10.1080/09273948.2022.2075761. Epub ahead of print. PMID: 35588311. Outer retinal features in OCT predict visual recovery after primary macula-involving retinal detachment repair. Hänsli C, Lavan S, Pfister IB, Schild C, Garweg JG. PLoS One. 2022 May 5;17(5):e0268028. doi: 10.1371/journal.pone.0268028. PMID: 35511781; PMCID: PMC9070941. Uveitisinduktion durch immunonkologische Therapien, speziell Checkpoint-Inhibitoren [Induction of Uveitis by Immune-Oncologic Therapies, Namely Checkpoint Inhibitors]. Garweg JG. Klin Monbl Augenheilkd. 2022 Apr;239(4):575-581. German. doi: 10.1055/a-1766-6119. Epub 2022 Apr 26. PMID: 35472809. Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial. Garweg JG, Štefanickova J, Hoyng C, Niesen T, Schmelter T, Leal S, Sivaprasad S; VIOLET Investigators. Adv Ther. 2022 Jun;39(6):2701-2716. doi: 10.1007/s12325-022-02119-z. Epub 2022 Apr 12. PMID: 35412227; PMCID: PMC9123040. Pathophysiological Considerations in Periorbital Necrotizing Fasciitis: A Case Report. Hadizamani Y, Anastasi S, Schori A, Lucas R, Garweg JG, Hamacher J. Ocul Immunol Inflamm. 2022 Apr 11:1-6. doi: 10.1080/09273948.2022.2032190. Epub ahead of print. PMID: 35404751.
RkJQdWJsaXNoZXIy MzQxOTE=